{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:59:13Z","timestamp":1789473553085,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.sapharm.2025.09.005","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T05:29:49Z","timestamp":1758950989000},"page":"171-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Health Belief Model Interventions in Pre-exposure Prophylaxis (PrEP): Untapped intervention in the pharmacy arena"],"prefix":"10.1016","volume":"22","author":[{"given":"Alina","family":"Cernasev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Angell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Derefinko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Cory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.sapharm.2025.09.005_bib1","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s10903-020-01138-8","article-title":"A review of cultural influences on risk for HIV and culturally-responsive risk mitigation strategies among African immigrants in the US","volume":"23","author":"Aidoo-Frimpong","year":"2021","journal-title":"J Immigr Minority Health"},{"issue":"7suppl 6","key":"10.1016\/j.sapharm.2025.09.005_bib4","article-title":"No one left behind: how are we doing in the roll-out of PrEP as part of combination HIV prevention?","volume":"19","author":"C\u00e1ceres","year":"2016","journal-title":"J Int AIDS Soc"},{"issue":"9839","key":"10.1016\/j.sapharm.2025.09.005_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0140-6736(12)61235-5","article-title":"FDA paves the way for pre-exposure HIV prophylaxis","volume":"380","author":"Holmes","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.sapharm.2025.09.005_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2055-6640(20)30312-5","article-title":"How safe is TDF\/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP","volume":"4","author":"Pilkington","year":"2018","journal-title":"J Eradication"},{"issue":"8","key":"10.1016\/j.sapharm.2025.09.005_bib7","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.2023.9865","article-title":"Preexposure prophylaxis for the prevention of HIV: updated evidence report and systematic review for the US preventive services Task force","volume":"330","author":"Chou","year":"2023","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.sapharm.2025.09.005_bib8","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1097\/QAD.0000000000001627","article-title":"Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries","volume":"31","author":"Hoornenborg","year":"2017","journal-title":"AIDS"},{"issue":"27","key":"10.1016\/j.sapharm.2025.09.005_bib9","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.sapharm.2025.09.005_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sapharm.2025.09.005_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40264-017-0505-6","article-title":"Pre-exposure prophylaxis for HIV prevention: safety concerns","volume":"40","author":"Tetteh","year":"2017","journal-title":"Drug Saf"},{"issue":"10246","key":"10.1016\/j.sapharm.2025.09.005_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.sapharm.2025.09.005_bib13","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1097\/QAI.0000000000002756","article-title":"Close, but not quite: one in twenty trans and gender diverse individuals assigned female at birth are being prescribed the wrong kind of PrEP","volume":"88","author":"Grov","year":"2021","journal-title":"JAIDS J Acquired Immune Deficiency Syndrom"},{"key":"10.1016\/j.sapharm.2025.09.005_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.664875","article-title":"Safety and pharmacokinetic profiles of long-acting injectable antiretroviral drugs for HIV-1 pre-exposure prophylaxis: a systematic review and meta-analysis of randomized trials","volume":"12","author":"Lazarus","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.sapharm.2025.09.005_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100303","article-title":"Safety and tolerability of injectable Rilpivirine LA in HPTN 076: a phase 2 HIV pre-exposure prophylaxis study in women","volume":"21","author":"Bekker","year":"2020","journal-title":"eClinicalMedicine"},{"issue":"7","key":"10.1016\/j.sapharm.2025.09.005_bib16","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","article-title":"Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial","volume":"7","author":"Landovitz","year":"2020","journal-title":"Lancet HIV"},{"issue":"11","key":"10.1016\/j.sapharm.2025.09.005_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002690","article-title":"Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial","volume":"15","author":"Landovitz","year":"2018","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.sapharm.2025.09.005_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s10461-022-03816-0","article-title":"The long-acting cabotegravir tail as an implementation challenge: planning for safe discontinuation","volume":"27","author":"Meyers","year":"2023","journal-title":"AIDS Behav"},{"key":"10.1016\/j.sapharm.2025.09.005_bib20","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons","author":"Kelley","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.sapharm.2025.09.005_bib21","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/10410236.2010.521906","article-title":"A meta-analysis of the effectiveness of health belief model variables in predicting behavior","volume":"25","author":"Carpenter","year":"2010","journal-title":"Health Commun"},{"issue":"1","key":"10.1016\/j.sapharm.2025.09.005_bib22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/her\/7.1.107","article-title":"A meta-analysis of studies of the health belief model with adults","volume":"7","author":"Harrison","year":"1992","journal-title":"Health Educ Res"},{"issue":"3","key":"10.1016\/j.sapharm.2025.09.005_bib23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/17437199.2013.802623","article-title":"Evaluating the effectiveness of health belief model interventions in improving adherence: a systematic review","volume":"8","author":"Jones","year":"2014","journal-title":"Health Psychol Rev"},{"key":"10.1016\/j.sapharm.2025.09.005_bib24","series-title":"The Health Belief Model and Personal Health Behavior","article-title":"Historical origins of the health belief model","author":"Rosenstock","year":"1974"},{"issue":"3","key":"10.1016\/j.sapharm.2025.09.005_bib25","doi-asserted-by":"crossref","DOI":"10.5210\/ojphi.v4i3.4321","article-title":"Towards an effective health interventions design: an extension of the health belief model","volume":"4","author":"Orji","year":"2012","journal-title":"Online J Public Health Inform"},{"issue":"3","key":"10.1016\/j.sapharm.2025.09.005_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/17437199.2013.802623","article-title":"Evaluating the effectiveness of health belief model interventions in improving adherence: a systematic review","volume":"8","author":"Jones","year":"2014","journal-title":"Health Psychol Rev"},{"issue":"3","key":"10.1016\/j.sapharm.2025.09.005_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034869","article-title":"Sample study protocol for adapting and translating the 5C scale to assess the psychological antecedents of vaccination","volume":"10","author":"Betsch","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.sapharm.2025.09.005_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/109019818401100101","article-title":"The health belief model: a decade later","volume":"11","author":"Janz","year":"1984","journal-title":"Health Educ Q"},{"issue":"1","key":"10.1016\/j.sapharm.2025.09.005_bib29","first-page":"28","article-title":"The health belief model","volume":"2","author":"Abraham","year":"2005","journal-title":"Predicting Health Behav"},{"key":"10.1016\/j.sapharm.2025.09.005_bib30","first-page":"1097","article-title":"STI prevention perspectives in black men who have sex with men taking PrEP in New Orleans","volume":"10","author":"Clement","year":"2023","journal-title":"Sex Transm Dis"},{"issue":"12","key":"10.1016\/j.sapharm.2025.09.005_bib31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.14423\/SMJ.0000000000001767","article-title":"Examining provider attitudes and barriers toward prescribing PrEP within primary care settings in Alabama","volume":"117","author":"McNellage","year":"2024","journal-title":"South Med J"},{"issue":"4","key":"10.1016\/j.sapharm.2025.09.005_bib32","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.japh.2019.12.003","article-title":"Pharmacy-based pre-exposure prophylaxis support among pharmacists and men who have sex with men","volume":"60","author":"Crawford","year":"2020","journal-title":"J Am Pharmaceut Assoc"},{"issue":"2","key":"10.1016\/j.sapharm.2025.09.005_bib33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1521\/aeap.2022.34.2.168","article-title":"HIV PrEP clinician communication preferences among black sexual minority men","volume":"34","author":"Dangerfield","year":"2022","journal-title":"AIDS Educ Prev"},{"issue":"1","key":"10.1016\/j.sapharm.2025.09.005_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262205","article-title":"\u201cIt's behaviors, not identity\u201d: attitudes and beliefs related to HIV risk and pre-exposure prophylaxis among transgender women in the southeastern United States","volume":"17","author":"Van Gerwen","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.sapharm.2025.09.005_bib35","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s10508-020-01684-0","article-title":"An exploration of pre-exposure prophylaxis (PrEP) initiation among women who inject drugs","volume":"49","author":"Felsher","year":"2020","journal-title":"Arch Sex Behav"},{"issue":"1","key":"10.1016\/j.sapharm.2025.09.005_bib36","first-page":"18","article-title":"Examining the health belief model risk factors on PrEP use among African-American women ages 20-44","volume":"30","author":"Nwogwugwu","year":"2019","journal-title":"J Natl Black Nurses' Assoc JNBNA: JNBNA"},{"issue":"5","key":"10.1016\/j.sapharm.2025.09.005_bib37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1521\/aeap.2018.30.5.369","article-title":"\u201cI don't need PrEP right now\u201d: a qualitative exploration of the barriers to PrEP care engagement through the application of the health belief model","volume":"30","author":"Felsher","year":"2018","journal-title":"AIDS Educ Prev"},{"issue":"4","key":"10.1016\/j.sapharm.2025.09.005_bib38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1037\/men0000258","article-title":"Psychosocial barriers to pre-exposure prophylaxis (PrEP) uptake: the roles of heterosexual self-presentation, sexual risk, and perceived peer prep use","volume":"21","author":"Parent","year":"2020","journal-title":"Psychol Men Masculinities"},{"issue":"7","key":"10.1016\/j.sapharm.2025.09.005_bib39","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2174\/1570162X12666140129104952","article-title":"Young adult women and correlates of potential adoption of pre-exposure prophylaxis (PrEP): results of a national survey","volume":"11","author":"Rubtsova","year":"2013","journal-title":"Curr HIV Res"},{"issue":"6","key":"10.1016\/j.sapharm.2025.09.005_bib40","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4103\/2141-9248.144914","article-title":"Determinants of patient's adherence to hypertension medications: application of health belief model among rural patients","volume":"4","author":"Kamran","year":"2014","journal-title":"Ann Med Health Sci Res"},{"issue":"1","key":"10.1016\/j.sapharm.2025.09.005_bib41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13548506.2021.1871770","article-title":"Predictors of adherence with home quarantine during COVID-19 crisis: the case of health belief model","volume":"27","author":"Al-Sabbagh","year":"2022","journal-title":"Psychol Health Med"},{"key":"10.1016\/j.sapharm.2025.09.005_bib42","first-page":"15","article-title":"Effects of education based on health belief model on dietary adherence in diabetic patients","volume":"9","author":"Piri","year":"2010","journal-title":"J Diabetes Metab Disord"},{"issue":"6","key":"10.1016\/j.sapharm.2025.09.005_bib43","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/add.15796","article-title":"Planning a change easily (PACE) for smokers who are not ready to quit: a telephone\u2010based, randomized controlled trial","volume":"117","author":"Derefinko","year":"2022","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.sapharm.2025.09.005_bib44","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/08824096.2023.2269080","article-title":"PrEP on TikTok: benefits, barriers, and possibilities","volume":"40","author":"Schwartz","year":"2023","journal-title":"Commun Res Rep"},{"key":"10.1016\/j.sapharm.2025.09.005_bib45","doi-asserted-by":"crossref","DOI":"10.2196\/43596","article-title":"Characterizing Twitter content about HIV pre-exposure prophylaxis (PrEP) for women: qualitative content analysis","volume":"25","author":"Keddem","year":"2023","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.sapharm.2025.09.005_bib46","series-title":"Associated Costs are a Barrier to HIV Preexposure Prophylaxis Access in the United States","first-page":"834","author":"Srikanth","year":"2022"},{"key":"10.1016\/j.sapharm.2025.09.005_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10410236.2025.2536314","article-title":"\u201cIt is in the air\u201d: seeking and scanning for information about pre-exposure prophylaxis among young-adult men who have sex with men in the US","author":"Skurka","year":"2025","journal-title":"Health Commun"},{"issue":"1","key":"10.1016\/j.sapharm.2025.09.005_bib48","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09540121.2015.1066749","article-title":"Shame among people living with HIV: a literature review","volume":"28","author":"Bennett","year":"2016","journal-title":"AIDS Care"},{"issue":"5","key":"10.1016\/j.sapharm.2025.09.005_bib49","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1080\/13691058.2021.1877824","article-title":"Women's views on communication with health care providers about pre-exposure prophylaxis (PrEP) for HIV prevention","volume":"24","author":"Jackson","year":"2022","journal-title":"Cult Health Sex"},{"issue":"3","key":"10.1016\/j.sapharm.2025.09.005_bib50","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/15381501.2020.1810838","article-title":"Factors influencing pre-exposure prophylaxis uptake among current users: a qualitative study","volume":"19","author":"Aidoo-Frimpong","year":"2020","journal-title":"J HIV\/AIDS Social Services"},{"issue":"3","key":"10.1016\/j.sapharm.2025.09.005_bib51","doi-asserted-by":"crossref","DOI":"10.1177\/1557988320919661","article-title":"The relationship between perception of HIV susceptibility and willingness to discuss PrEP with a health care provider: a pilot study","volume":"14","author":"Carter","year":"2020","journal-title":"Am J Mens Health"},{"issue":"1","key":"10.1016\/j.sapharm.2025.09.005_bib52","doi-asserted-by":"crossref","DOI":"10.52504\/001c.127951","article-title":"Patient-provider satisfaction and combination antiretroviral therapy adherence: an analysis of the association between health care satisfaction and adherence, as framed by the health belief model","volume":"8","author":"Graham","year":"2025","journal-title":"Georgetown Med Rev"},{"issue":"5","key":"10.1016\/j.sapharm.2025.09.005_bib53","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1743-6109.2012.02702.x","article-title":"What we don't talk about when we don't talk about sex 1: results of a national survey of US obstetrician\/gynecologists","volume":"9","author":"Sobecki","year":"2012","journal-title":"J Sex Med"},{"issue":"4","key":"10.1016\/j.sapharm.2025.09.005_bib54","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2524.2005.00566.x","article-title":"\u2018I daresay I might find it embarrassing\u2019: general practitioners' perspectives on discussing sexual health issues with Lesbian and gay patients","volume":"13","author":"Hinchliff","year":"2005","journal-title":"Health Soc Care Community"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741125004541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741125004541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:44:42Z","timestamp":1763768682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741125004541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1551741125004541"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2025.09.005","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Belief Model Interventions in Pre-exposure Prophylaxis (PrEP): Untapped intervention in the pharmacy arena","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2025.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}